Metagenomi Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $30.57M
- P/E (TTM)
- –
- Dividend yield
- –
About Metagenomi Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Metagenomi Therapeutics, Inc. is a genetic medicines company that develops next-generation genome editing systems to create curative therapies for patients. The company focuses on research and development efforts in genome editing using programmable nucleases, base editing, and RNA- and DNA-mediated integration systems, which include prime editors and CRISPR-associated transposases. It has not yet commercialized any product candidates and conducts research and development activities through strategic collaborations and license agreements with pharmaceutical partners such as Ionis and Moderna.
The company operates in a single operating segment focused on the development of its genome editing platform and therapies. It conducts preclinical studies and development programs in the United States and has established collaborations with third-party partners. Metagenomi Therapeutics, Inc. maintains its principal executive offices and laboratory facilities in Emeryville, California.
Summary of the business section of Metagenomi Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Metagenomi Therapeutics, Inc.
- Headquarters
- Emeryville, CA
- Address
- 5959 Horton Street, 7th Floor 94608
- Phone
- (510) 871-4880
- Website
- ir.metagenomi.co
- Employees
- 119, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- MGX
- Exchange
- Nasdaq
- IPO date
- Feb 12, 2024
- Shares outstanding
- 38M, Aug 6, 2026
- Public float
- $50.93M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1785279
- CUSIP
- 59102M104
- ISIN
- US59102M1045
- EIN
- 81-3909017
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jian Irish | See Remarks, Director | 668,107 |
| Matthew Wein | See Remarks | 126,133 |
| Pamela Wapnick | Chief Financial Officer | 206,580 |
| Sarah B. Noonberg | Chief Medical Officer | 109,135 |
| Laurence Reid | Director | 20,000 |
| Eric Bjerkholt | Director | – |
| Willard H. Dere | Director | 51,275 |
| Juergen Eckhardt | Director | – |
| Brian C. Thomas | Director | 2,510,960 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 119 full-time employees, of which 39 have M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 12, 2026 | Name change | Name changed from Metagenomi, Inc. to Metagenomi Therapeutics, Inc. |
| Feb 12, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 5, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jan 18, 2024 | Name change | Name changed from Metagenomi Technologies, LLC to Metagenomi, Inc. |